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ABSTRACT
Objective: The study goal was to assess the benefits and potential limitations in the use of ultrasmall
superparamagnetic iron oxide (USPIO) nanoparticles in the MRI diagnosis of CNS inflammatory dis-
eases and primary CNS lymphoma.
Methods: Twenty patients with presumptive or known CNS lesions underwent MRI study. Eighteen
patients received both gadolinium-based contrast agents (GBCAs) and 1 of 2USPIO contrast agents
(ferumoxytol and ferumoxtran-10) 24 hours apart, which allowed direct comparative analysis. The
remaining 2 patients had only USPIO-enhanced MRI because of a renal contraindication to GBCA.
Conventional T1- and T2-weighted MRI were acquired before and after contrast administration in
all patients, and perfusion MRI for relative cerebral blood volume (rCBV) assessment was obtained
in all 9 patients receiving ferumoxytol.
Results: USPIO-enhancedMRI showed an equal number of enhancing brain lesions in 9 of 18 patients
(50%), more enhancing lesions in 2 of 18 patients (11%), and fewer enhancing lesions in 3 of 18
patients (17%) compared with GBCA-enhanced MRI. Four of 18 patients (22%) showed no MRI
enhancement. Dynamic susceptibility-weighted contrast-enhanced perfusion MRI using ferumoxytol
showed low rCBV (ratio ,1.0) in 3 cases of demyelination or inflammation, modestly elevated rCBV
in 5 cases of CNS lymphoma or lymphoproliferative disorder (range: 1.3–4.1), and no measurable
disease in one case.
Conclusions: This study showed that USPIO-enhanced brainMRI can be useful in the diagnosis of CNS
inflammatory disorders and lymphoma, and is also useful for patients with renal compromise at risk of
nephrogenic systemic fibrosis who are unable to receive GBCA. Neurology 2013;81:256–263
GLOSSARY
CNSL 5 CNS lymphoma; DSC 5 dynamic susceptibility-weighted contrast-enhanced; GBCA 5 gadolinium-based contrast agent;
NSF 5 nephrogenic systemic fibrosis; PCNSL 5 primary CNS lymphoma; PTLD 5 posttransplant lymphoproliferative disorder;
PWI 5 perfusion-weighted imaging; rCBV 5 relative cerebral blood volume; USPIO 5 ultrasmall superparamagnetic iron oxide.
CNS lymphoma (CNSL) presents a diagnostic challenge.1–9 Brain MRI typically reveals a single
nodule or multiple nodules in the deep parenchyma that enhance with IV contrast.5,9–11 Unfortu-
nately, CNSL mimics other diseases on routine neuroimaging, including CNSmetastasis of systemic
cancer, glioma, and demyelination, often leading to aggressive surgical approaches and/or delay in
tissue diagnosis and treatment.12–14 Obtaining a tissue diagnosis in the least-invasive manner possible
is critically important because CNSL is typically chemosensitive, infiltrative, and often in a deep
location within the brain parenchyma.15,16
Use of a gadolinium-based contrast agent (GBCA) enables contrast-enhanced T1-weighted MRI
as the GBCA permeates an incompetent blood-brain barrier. Unlike GBCA, ultrasmall superpara-
magnetic iron oxide (USPIO) nanoparticles act as blood pool agents immediately after administra-
tion, but they are later taken up by inflammatory cells (e.g., macrophages), acting as an intracellular
contrast agent, with abnormal parenchymal enhancement that peaks 24 hours after administra-
tion.17 In this study, we assessed both the benefits and limitations regarding the use of USPIO
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nanoparticles as contrast agents for anatomical
and perfusion MRI in the diagnosis of CNS
inflammatory diseases and primary CNSL. We
propose that these agents may improve MRI
visualization of CNSL and CNS inflammatory
disease and help to establish the most informa-
tive target for biopsy. Unlike GBCA, USPIO
may also be used safely in patients with renal
failure.
METHODS Standard protocol approvals, registrations, and
patient consents. The study was registered with and approved by
the Oregon Health & Science University Institutional Review Board
(eIRB no. 1562). The study was sponsored by the NIH, and all
participants provided written informed consent.
Study population. Twenty patients with CNSL or CNS
inflammatory disease were enrolled as part of an ongoing pro-
spective study. Between November 2002 and May 2011, eligi-
ble patients with suspected CNS tumors, demyelinating disease,
or any CNS lesion with an inflammatory component underwent
MRI after USPIO administration. Diagnoses were confirmed his-
tologically (n 5 19) or by characteristic clinical and radiographic
findings and subsequent improvement on surveillance (n 5 1).
Exclusion criteria have been reported previously.18,19 Patients who
were HIV positive receiving combination antiretroviral therapy
were ineligible because of the potential for pharmacokinetic inter-
actions with USPIO agents.
MRI examination. All MRI scans were performed on a
3-tesla whole-body MRI system (TIM TRIO; Siemens, Erlan-
gen, Germany) with a body radiofrequency coil transmitter
and a 12-channel matrix head coil signal receiver. Specific
MRI acquisition parameters are provided in table e-1 on the
Neurology® Web site at www.neurology.org. The imaging
protocol consisted of 3 consecutive days of MRI scans. On
the first day, T1- and T2-weighted pre- and postcontrast
sequences were acquired using gadoteridol gadolinium (III)
chelate (ProHance; Bracco Diagnostics Inc., Princeton, NJ),
with the exception of 2 subjects with renal insufficiency
(estimated glomerular filtration rate ,30 mL/min/1.73 m2)
who did not receive gadoteridol and instead underwent only a
2-dayMRI protocol with USPIO as the contrast agent. Gadoteridol
was injected as an IV bolus at a dose of 0.1 mmol/kg body
weight. On the following day, the same MRI sequences were
obtained using ferumoxytol (n 5 9) (AMAG Pharmaceuticals,
Inc., Cambridge, MA) or ferumoxtran-10 (n 5 11) (AMAG
Pharmaceuticals, Inc.). Ferumoxtran-10 preceded ferumoxytol,
with similar MRI properties. Manufacturing of ferumoxytran-10
was discontinued when ferumoxytol became available.
Ferumoxtran-10 (2.6 mg/kg) was diluted in 90 mL of
saline and infused at 4 mL/min. All contrast dosages have
been used in previous human and preclinical studies.
Patients who received ferumoxytol also underwent dynamic
susceptibility-weighted contrast-enhanced (DSC) perfusion MRI
(n5 9) because ferumoxytol can be administered via rapid IV bolus
injection. The 11 patients who received ferumoxtran-10 were
unable to have perfusion-weighted imaging (PWI) since this con-
trast agent cannot be given via rapid IV bolus because of the risk of
anaphylactoid reactions. The total ferumoxytol dose (510 mg) was
diluted in 17 mL of saline. First, 75 mg of ferumoxytol was admin-
istered as an IV bolus during DSC-MRI acquisition. Then, patients
received the remainder of the dose (435 mg) over 15 minutes. After
USPIO administration, all patients were monitored closely for 2
hours. On the third day, at least 22 hours after USPIO agent
administration, T1- and T2-weighted imaging sequences were
repeated to detect delayed USPIO-induced signal changes. All
patients were followed for 1 month to note possible adverse
reactions.
Image analysis. All images from each patient were evaluated in a
matched-pair fashion by the same neuroradiologist. Image assessment
consisted of the following steps: 1) quantification of the total number
of enhancing brain lesions on the T1-weighted gadoteridol-enhanced
scan compared with the noncontrast T1-weighted scan; 2) quan-
tification of brain lesions on T1- and T2-weighted scans 24 hours
after USPIO administration compared with noncontrast T1- andT2-
weighted scans; and 3) evaluation of postcontrast USPIO and GBCA
scans for leptomeningeal disease.
All first-pass DSC-MRI data were processed using Lupe (Lund
University Perfusion Evaluation, Sweden) perfusion image analysis
software and the simple singular value decomposition–based calcu-
lation method as described by Ostergaard et al.,20 uncorrected for
contrast leakage. Arterial input function was determined from the
middle cerebral artery contralateral to the enhancing lesion. Color-
coded relative cerebral blood volume (rCBV) maps were created on
a voxel-wise basis. Normal white matter within the contralateral
hemisphere was used as the internal reference standard; rCBV values
were calculated by dividing the maximal rCBV in the enhancing
lesion by that of contralateral normal-appearing white matter.
RESULTS The summary data (table 1) show the com-
parative results of MRI with USPIO and with GBCA.
Two patients with renal insufficiency were given only
USPIO-based contrast because of the known risk of
nephrogenic systemic fibrosis (NSF) with GBCA.17 Nine
of 18 patients (50%) who received both contrast agents
showed equal numbers of enhancing lesions on
T1-weighted postcontrast images when comparing
GBCA- with USPIO-based MRI contrast. Two of 18
patients (11%) who received USPIO-based contrast
showed additional enhancement not visible with GBCA.
Three of 18 patients (17%) demonstrated areas of
enhancement when given GBCA that were not apparent
on USPIO-enhanced scans. Four of 18 patients (22%)
showed no enhancement with either agent.
Postcontrast MRIs from 15 patients with CNS lym-
phoid malignancies, either posttransplant lymphoproli-
ferative disorder (PTLD) or CNSL, were also reviewed
for leptomeningeal disease. Two patients showed local-
ized leptomeningeal enhancement on post-USPIO imag-
ing around the primary tumor site, but only one of these
showed comparable leptomeningeal enhancement with
GBCA. We did not see diffuse leptomeningeal enhance-
ment in any case.
Nine patients who received ferumoxytol were able to
undergo perfusion MRI, and rCBV values were deter-
mined. Eight of those 9 patients had enhancing lesions
amenable for rCBV calculation, whereas one postther-
apy patient did not. The rCBV values in CNSL and
PTLD were variable and ranged from 1.3 to 4.1,
whereas demyelinating lesions demonstrated low rCBV
values less than 1.0.
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Several observations highlight the potential use of USPIO-
based contrast studies. Scenario 1: Improved targeting of surgical
biopsy. Case 1. As an example of intense iron labeling using
USPIO-based contrast compared with GBCA, we evalu-
ated a 59-year-old woman who presented with progress-
ive memory loss and confusion (table 1, patient 1). An
initial MRI with GBCA showed multifocal, avidly
enhancing, deep white matter lesions consistent with
demyelinating disease or primary CNSL (figure 1B).
Nondiagnostic cytologic studies promptedUSPIO-based
MRI. The T1-weighted images showed similar patterns
of contrast enhancement between GBCA- and USPIO-
enhanced images (figure 1, B and C). The T2-weighted
images (figure 1, D and E) highlight key differences
between USPIO-based contrast and GBCA. After
USPIO administration, iron uptake by inflammatory
cells appears profoundly hypointense in the centers of
lesions (figure 1E) that are otherwise hyperintense on
noncontrasted T2-weighted MRI (figure 1D). The
patient underwent stereotactic needle biopsy of the
right frontal T2-hypointense lesion seen on the post-
ferumoxytol scan, which confirmed the suspected diag-
nosis of diffuse large B-cell lymphoma.
Case 2. A 30-year-old woman presenting with several
weeks of fatigue and confusion was referred with a pro-
visional diagnosis of CNSL (table 1, patient 2). Neuro-
logic examination showed gait instability. MRI showed
an area of T2 signal abnormality and enhancement in
the right deep frontal white matter and basal ganglia
extending into the hypothalamus on post-GBCA T1-
weighted images (figure 2, A and B). After nondiagnostic
lumbar puncture, a stereotactic needle biopsy was per-
formed, targeting the enhancement on the post-GBCA
T1-weighted scan. Histologic evaluation showed only
gliosis. The patient subsequently underwent USPIO-
enhanced MRI. Ferumoxytol-enhanced T1-weighted
images showed a similar enhancement pattern compared
with GBCA. However, the USPIO images revealed a
hypointense focus on T2-weighted images that was not
visible on the GBCA-enhanced scan (figure 2C). She
underwent repeat stereotactic needle biopsy targeting
the area of T2-weighted hypointense signal, which re-
vealed demyelination with intact axons, suggesting a
diagnosis of multiple sclerosis.
Scenario 2: Avoidance of NSF.NSF is an idiopathic and
potentially fatal complication that may occur after
Table 1 Summary dataa
Patient Diagnosis
No. of study
MRIs
Enhancing lesions
1 GBCA
Enhancing lesions
1 USPIO
Relative cerebral blood
volume 1 USPIO
1 (figure 1) PCNSL 1 3 3 2.3
2 (figure 2, A–C) MS 1 1 1 0.3
3 (figure 2, D and E) PTLD 1 1 1 1.3
4 (figure 3) Acute demyelinating encephalomyelitis 1 Not done 1 0.9
5 (figure 2, F–I) Tumefactive demyelination 1 3 3 0.4
6 (figure 4) PTLD 2 6 4, 3 2.1
7 Lymphoid infiltrateb 1 Not done 0
8 Chronic encephalitis 1 3 5
9 PCNSL 1 5 5
10 PCNSL 1 5 0
11 PTLD 3 2 2 4.1
12 PCNSL 1 1 1
13 PCNSL 1 0 2
14 CNSLb 1 0 0 No lesion; post-Tx
15 PCNSL 1 1 1
16 PCNSL 1 0 0
17 PCNSL 1 0 0
18 PCNSL 1 Many Many 1.4
19 PCNSL 1 0 0
20 PCNSL 1 3 2
Abbreviations: CNSL 5 CNS lymphoma; GBCA 5 gadolinium-based contrast agent; MS 5 multiple sclerosis; PCNSL 5 primary CNSL; PTLD 5 posttrans-
plant lymphoproliferative disorder; Tx 5 treatment; USPIO 5 ultrasmall superparamagnetic iron oxide.
a Twenty patients with CNS inflammatory disease underwent imaging studies. There were no significant toxicities observed in any patient treated with
USPIO. Numbers separated by commas represent the number of enhancing lesions followed on serial MRI scans. The last column shows relative cerebral
blood volume values for patients who underwent perfusion imaging after administration of ferumoxytol contrast.
b Patient with a history of systemic lymphoma.
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gadolinium administration in patients with renal insuf-
ficiency. The proposed mechanism for development of
such fibrosis involves decreased renal clearance of GBCA
resulting in deposition in the skin and other organs. The
end result is multiorgan fibrosis causing skin contrac-
tures, intense pruritus, and potential cardiac and respira-
tory failure.17 The risk of NSF led the US Food and
Drug Administration to recommend that no GBCA be
given to any patient with an estimated glomerular filtra-
tion rate less than 30 mL/min/1.73 m2, or to any renal
transplant patient—a policy that is strictly adhered to by
most practicing radiologists and adopted by the Amer-
ican College of Radiology.21 Therefore, USPIOs, which
are already used as iron replacement in dialysis patients,
are an attractive alternative to GBCAs in such patients.
Case 3.To avoid the potential consequences of NSF,
we enrolled a 67-year-old renal transplant patient with
suspected CNS PTLD in the USPIO-based MRI
protocol (table 1, patient 3). Images acquired before treat-
ment (figure 2D) showed a left-frontal enhancing mass
consistent with PTLD, which was confirmed with
biopsy. She had previously undergone MRI with GBCA
(at another institution, despite her history of renal
transplant) and this showed a similar appearance; how-
ever, the subsequent use of USPIO-based contrast
enabled her to have follow-up without the risk of NSF.
USPIO-based MRI, repeated 1 year after the biopsy (fig-
ure 2E), showed an excellent response to monotherapy
with rituximab.
Scenario 3: Correlating cerebral blood volume and CNS
inflammation. Case 4.A 23-year-old woman presented with
a right homonymous hemianopsia and a rapidly expand-
ing left occipital lesion on standard MRI with GBCA
(table 1, patient 5; figure 2G). A craniotomy was
planned for resection of the lesion. Before surgery, she
was evaluated with USPIO-based perfusion imaging and
this showed low blood volume (rCBV5 0.4; figure 2I).
Because the GBCA-based imaging suggested that the
enhancing mass was high-grade neoplasm but low blood
volume was noted upon perfusion imaging, the decision
wasmade to instead perform a needle biopsy. The biopsy
revealed destruction of myelin with intact axons, and
CSF studies showed oligoclonal bands with an increased
immunoglobulin G synthesis rate. The neurology team
then managed her tumefactive demyelination.
Case 5.A 30-year-old man with end-stage renal disease
due to uncontrolled type 1 diabetes (serum creatinine5
3.0 mg/dL) presented with episodic headaches and
altered mental status, but he was neurologically intact
at presentation (table 1, patient 4). Noncontrast MRI
revealed an expansile lesion in the pons. GBCAMRIwas
contraindicated because of the risk of NSF. He under-
went imaging before and 24 hours after the administra-
tion of ferumoxytol (figure 3, A and B); USPIO contrast
images showed intense USPIO uptake in the pons,
which correlated with hyperintense T2-weighted signal
abnormality on precontrast imaging (figure 3C).
T2-weighted images after USPIO contrast showed
hypointense foci (figure 3D). USPIO-based perfusion
MRI demonstrated low blood volume (rCBV 5 0.9)
(figure 3E), which we interpreted to favor non-neoplastic
pathology. Rather than proceed with a potentially mor-
bid biopsy, follow-up MRI at 6 weeks and 6 months
were obtained, and showed that the lesion had regressed.
A presumptive diagnosis of acute demyelinating enceph-
alomyelitis was made by neurologic consultants.
Scenario 4: Potential limitations in imaging after USPIO
administration—CNSL and venous thromboembolism. Case 6.
A 63-year-old woman underwent USPIO-based MRI
as part of evaluation of brainstem PTLD (table 1,
patient 6). T2-weighted images 24 hours after USPIO
administration showed a markedly hypointense signal
suggesting intense iron uptake by lymphoid cells
(figure 4B) and the diagnosis was confirmed with
biopsy. The patient tolerated PTLD treatment well
and was neurologically stable. One month after treat-
ment, she developed a deep vein thrombosis; MRI
(without contrast) was performed before initiation of
anticoagulation. T2-weighted MRI showed focal
Figure 1 MRIs of patient with primary CNSL
MRIs from case 1. (A) T1-weighted MRI without contrast agent. (B) T1-weighted MRI imme-
diately after administration of GBCA shows multifocal, enhancing, deep white matter lesions
(arrows) suggesting primary CNSL. Note, however, that the relatively minimal mass effect for
lesion extent and incomplete enhancing rims are more typical of demyelinating disease. (C)
T1-weighted MRI 24 hours after administration of USPIO contrast shows more extensive
enhancement because of phagocytic cellular uptake (arrows) than the GBCA-enhanced scan.
(D) T2-weighted MRI without contrast shows multifocal confluent areas of T2 hyperintensity
in white matter. (E) T2-weighted MRI 24 hours after ferumoxytol shows multiple areas of
intense USPIO uptake (arrows). CNSL5CNS lymphoma; GBCA5 gadolinium-based contrast
agent; USPIO 5 ultrasmall superparamagnetic iron oxide.
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hypointensity (figure 4C) concerning for brainstem
hemorrhage. This resulted in placement of an IV filter
instead of anticoagulation therapy. However, it is
important to recognize that acute brainstem hemor-
rhage was highly unlikely given the patient’s stable
neurologic examination. The findings were thought
to represent residual USPIO contrast, given relatively
diminished similar pattern of signal abnormality to
prior ferumoxytol-enhanced MRI with overall
decreased mass effect. Noncontrast head CT per-
formed within 24 hours confirmed no hyperdensity
in the brainstem to suggest recent hemorrhage. Surveil-
lance MRI scans (without contrast) at 3 months
showed continued decrease in T2 signal hypointensity
(figure 4D).
DISCUSSION USPIO-enhanced MRI offers a number
of potential advantages over conventional GBCA-
enhanced MRI in the diagnostic workup of CNSL
and inflammatory intracranial neoplastic mimics. First,
USPIO-enhanced MRI may offer different or addi-
tional areas of enhancement that may offer improved
Figure 2 USPIO imaging of CNS inflammation
(A–C) MRIs from case 2. (A) T1-weighted MRI shows GBCA enhancement in the inferior right basal ganglia and hypothalamus
(arrow). (B) T2-weighted MRI without contrast agent shows the first biopsy tract (arrow) targeting regions of GBCA enhance-
ment on T1-weighted images. (C) T2-weighted MRI, 24 hours after administration of ferumoxytol, shows a markedly hypo-
intense area suggesting the area of maximal iron uptake (arrow), which was the target of a second biopsy revealing
demyelination. (D and E) MRIs from case 3, a patient with PTLD. (D) Pretreatment images: T1-weightedMRI (i) and T2-weighted
MRI (ii) 24 hours after administration of ferumoxytol. Arrows show areas of intense iron uptake on both sequences. (E)
Posttreatment images: T1-weighted MRI (i) and T2-weighted MRI (ii) 24 hours after administration of ferumoxytol show
resolved enhancement and mass effect. (F–I) MRIs from case 4. (F) Precontrast axial T1-weighted MRI shows mild T1 hypo-
intensity (arrow) andmass effect in the left occipital lobe. (G) Post-GBCAT1-weighted axial MRI shows patchymarginal nodular
enhancement (arrow) raising concern for potential high-grade malignancy. (H) Precontrast T2-weighted axial MRI shows vaso-
genic edema consistent with high-grade glioma. (I) rCBVmap obtained after administration of USPIO contrast shows low rCBV
(arrow) in the lesion that would be atypical for high-grade glioma. Biopsy confirmed diagnosis of tumefactive demyelination.
GBCA5 gadolinium-based contrast agent; PTLD5 posttransplant lymphoproliferative disorder; rCBV5 relative cerebral blood
volume; USPIO 5 ultrasmall superparamagnetic iron oxide.
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surgical targeting opportunities. This may be partic-
ularly true for T2-weighted enhanced scans withUSPIO,
which may offer an alternative sampling site for biopsy to
conventional postcontrast T1-weighted scans with
GBCA. Second, ferumoxytol-based DSC PWImay offer
discrimination of inflammatory diseases such as demyeli-
nation from neoplastic disorders. Third, USPIO can be
safely used in patients with renal failure who cannot
receive GBCA.
Based on our prior work, immediate post-USPIO
MRI shows intravascular, not abnormal parenchymal
enhancement.22–24 The second day of imaging at 24
hours is a relatively intracellular-weighted (and/or inter-
stitial-weighted) rather than intravascular-weighted
MRI given that ferumoxytol has an intravascular half-
life of approximately 14 to 20 hours.25 This proved
helpful in one patient in this series who underwent a
second diagnostic biopsy in which a different surgical
target was selected based on the T2-weighted USPIO-
enhanced MRI.
Preclinical studies in animal models have shown via
histologic analysis that hypointense foci on delayed (24
hours) T2-weighted MRI in the brain correspond with
iron staining of phagocytic cells (such as macrophages),
and efforts to confirm these findings in human biopsy
specimens are ongoing.25,26 Abnormal parenchymal
enhancement with GBCA, by contrast, is due to
increased vascular permeability from blood-brain bar-
rier breakdown.25 Future studies are needed to confirm
the localization of ferumoxytol in human tissues.
Determining whether localization is primarily within
inflammatory phagocytic cells (intracellular) or intersti-
tial (due to slower extravascular leakage compared with
GBCA) remains an ongoing project.
DSC-based perfusion studies in this series were based
only on ferumoxytol because it can be given via IV bolus
injection without the risk of anaphylactoid reactions due
to mast cell degranulation that were relatively common
with earlier iron oxide nanoparticle preparations such as
ferumoxtran-10. In the literature, DSC-based PWI of
CNSL has shown variable results using GBCA, with val-
ues overlapping with respect to malignant glioma in pub-
lished studies.14 Our results are consistent with reported
findings in which demyelinating or inflammatory lesions
show low rCBV27 whereas CNSL demonstrates modestly
elevated rCBV values that do not permit reliable differ-
entiation from high-grade glioma.12 Our experience with
ferumoxytol-based DSC perfusion in malignant gliomas
Figure 3 MRIs of patient with headaches and altered mental status unable to receive GBCA because of renal
failure
MRIs from case 5. (A) Precontrast T1 imaging shows mild pontine expansion and slightly decreased T1 signal throughout. (B)
T1-weighted sagittalMRI 24 hours post-USPIO shows intense iron uptake in the pons (arrow). (C) An axial T2-weighted precon-
trast image shows patchy nonspecific increased T2 signal within the pons (arrow). (D) An image 24 hours post-USPIO shows
patchy hypointensities in the pons (arrow) correlating with iron uptake. (E) USPIO-based DSC perfusion imaging shows low
rCBV centrally within the pons (arrow) corresponding to the area of enhancing abnormality that is similar to normal-appearing
white matter. DSC5 dynamic susceptibility-weighted contrast-enhanced; GBCA5 gadolinium-based contrast agent; rCBV5
relative cerebral blood volume; USPIO 5 ultrasmall superparamagnetic iron oxide.
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has shown higher reliability than GBCA-based DSC
PWI. USPIO-based DSC perfusion requires neither
expensive leakage correlation software algorithms nor pre-
loading with additional doses of USPIO, as is necessary
with GBCA.24 Our limited number of PWIs in CNSL
cases in this series do not allow generalization, but will be
a subject of future study.
Two subjects in this series underwent USPIO-
enhanced MRI because they were unable to receive
GBCA at our institution due to risk of NSF. This sit-
uation may be particularly problematic for renal trans-
plant patients, who are at risk of both NSF and PTLD,
given immunosuppression. Ferumoxytol-enhanced
MRI offers a diagnostic opportunity without the atten-
dant risks.
Limitations of USPIO-enhanced MRI include the
following: 1) requirement for at least 2 consecutive days
of imaging to obtain anatomical “enhanced” scans sim-
ilar to GBCA-enhanced MRI, 2) ferumoxytol-based
DSC perfusion MRI, similar to GBCA-based DSC per-
fusion MRI, remains unable to discriminate between
malignant lymphoid and glial neoplasms, and 3) poten-
tial for USPIO enhancement to persist up to several
months after injection may result in confusion for hem-
orrhage. However, increased use of USPIO-based
imaging agents over time will surely result in awareness
of this possibility. Likely because of this known uncom-
mon effect, the package insert for ferumoxytol warns
prescribers that the compound can “alter MRI studies”
for up to 3 months.28 Nevertheless, the US federal gov-
ernment continues to fund multiple clinical studies
investigating the MRI-based applications of ferumox-
ytol.29 This labeling unfortunately creates a per-
ception that ferumoxytol administration is
contraindicated when, in fact, an MRI may be desir-
able. Clinicians and radiologists should be made
aware of any prior USPIO administration, however,
in order to allow proper interpretation of MRI stud-
ies. Noncontrast head CT may also resolve any ques-
tion of hemorrhage, as in the case presented here.
Our experience highlights the benefits and limitations
of the use of USPIO-basedMRI, which provides relevant
information in CNS inflammation and neoplastic dis-
eases.24,30 Our preliminary findings of USPIO-enhanced
imaging in CNSL require further evaluation in studies
involving systemic lymphoma. Importantly, USPIO
imaging provides a safe alternative for MRI in patients
with renal failure. Based on these findings, the US Food
and Drug Administration label should encourage, not
deter, further use of USPIO agents in the setting ofMRI.
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Figure 4 T2-weighted MRIs of patient with PTLD showing prolonged duration of
iron labeling
MRIs from case 6. (A) Pretreatment imagewithout contrast shows increased T2 signal abnormal-
ity and mild mass effect in the pons and right cerebellum. (B) T2-weighted image 24 hours after
initial ferumoxytol imaging shows intense iron uptake (arrow). Reprintedwith permission from the
American Journal of Roentgenology.19 (C) After 1month, the patient underwent noncontrastMRI
after diagnosis of deep vein thrombosis. T2 hypointense areas (arrow) were initially misinter-
preted as asymptomatic brainstem hemorrhage but likely represented residual iron-labeled
inflammatory cells because a noncontrast CT showed no hyperdensity in the brainstem (not
shown). (D) Punctate T2 hypointense signal remained (arrow), but was diminished 3months after
ferumoxytol administration. PTLD 5 posttransplant lymphoproliferative disorder.
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